EPIC THERAPEUTICS
EPICS Therapeutics develop novel therapeutic solutions for cancer, based on the highly innovative field of RNA epigenetics.
EPIC THERAPEUTICS
Industry:
Biopharma Health Care
Founded:
2018-01-01
Address:
Gosselies, Hainaut, Belgium
Country:
Belgium
Website Url:
http://www.epicstherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+32 71 348 500
Email Addresses:
[email protected]
Total Funding:
7.2 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Apache Euro
Similar Organizations
Aerogen
Aerogen is a medical device and drug delivery company.
Blade Therapeutics
Blade Therapeutics is a discovery stage drug development company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
iOx Therapeutics Ltd.
iOx Therapeutics Ltd. operates as an immuno-oncology company.
ZWI Therapeutics, Inc.
ZWI Therapeutics is a biotech company developing a new polymer to reduce immunogenicity and aid pharmacokinetics of protein therapeutics.
Current Employees Featured
Founder
Investors List
S.R.I.W.
S.R.I.W. investment in Seed Round - Epic Therapeutics
Official Site Inspections
http://www.epicstherapeutics.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Epic Therapeutics"
Epic Therapeutics - Crunchbase Company Profile
Organization. Epic Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact …See details»
EPICS Therapeutics names Franz Obermayr Ph. D., …
Jan 31, 2022 After the successful development of Ogeda since 2006 (initially Euroscreen) and its sale to Astellas Inc. in 2017, Jean was a founder and the driving force of EPICS Therapeutics since 2018, building a strong drug …See details»
EPICS Therapeutics - LinkedIn
EPICS Therapeutics Biotechnology Research Gosselies, Wallonie 1,183 followers EPICS is a drug discovery and development company for small molecule drugs targeting RNA epigenetic mecanisms of cancerSee details»
EPICS Therapeutics Appoints Graeme Fraser PhD, Chief …
Oct 18, 2024 Gosselies, Belgium – October 18th, 2024 EPICS Therapeutics announced today that its Board of Directors has appointed Graeme Fraser, PhD, as the Company’s Chief Executive Officer. He will also join EPICS …See details»
EPICS Therapeutics - VentureRadar
"EPICS is a drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development.See details»
EPICS Therapeutics Overview | SignalHire Company Profile
Organization Website: epicstherapeutics.com : Contact Email [email protected] Phone Number +32 71 348 500: EPICS Therapeutics industries Biotech: Headquarters Location: 47 Adrienne …See details»
EPICS Therapeutics - Portfolio Company Profile, Executives and …
See EPICS Therapeutics's complete profile, including its private equity owner and the number of its executive contacts in our database. EPICS is a drug discovery and development company …See details»
Epics Therapeutics SA
PARIS--( BUSINESS WIRE )--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for …See details»
Epics Therapeutics - PitchBook
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20240270716-A1: Piperidine derivatives as mettl3 inhibitors: Active: 20-Jan-2023See details»
EPICS Therapeutics - Craft
EPICS Therapeutics has 5 employees across 2 locations and $8.44 m in total funding,. See insights on EPICS Therapeutics including office locations, competitors, revenue, financials, …See details»
EPICS Therapeutics Names Franz Obermayr Ph. D., Chief ... - BioPark
And development organization and successfully ushering drug candidates into clinical development. The Board of Directors is convinced that under Franz Obermayr’s leadership the …See details»
EPICS Therapeutics - Company Profile & Staff Directory - ContactOut
EPICS is a drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development. EPICS’s …See details»
EPICS Therapeutics to acquire Ogeda former assets, Adding Drug ...
Jan 3, 2019 Brussels, Belgium, December 21st, 2018 EPICS Therapeutics SA, a recently launched biotech company (April 2018) focused on discovery and development of innovative …See details»
Epics Therapeutics - Sambrinvest
Nouvelle spin-off de l’ULB, EPICS Therapeutics est issue des travaux de recherche du Professeur François Fuks, directeur du Laboratoire d'Épigénétique du Cancer de la Faculté de Médecine …See details»
EPICS Therapeutics The RNA epigenetic Cancer Company - DAILY …
EPICS Therapeutics – The RNA epigenetic Cancer Company Belgium, May 24, 2018 EPICS Therapeutics is a newly created company dedicated to develop novel therapeutic solutions for …See details»
Epics Therapeutics Initiates First-in-Human Studies with ... - BioPark
GPS +50° 28' 17.4"N, +4° 28' 15.7"E www.epicstherapeutics.com Bank account : 001 8338421 86 Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug …See details»
EPICS Therapeutics initiates first-in-human studies with EP282, an …
Gosselies, Belgium, January 12th, 2022 EPICS Therapeutics SA, a private drug development company, announced today the initiation of a first-in-human, double-blind, placebo-controlled, …See details»
Epicrispr raises $68 million from Lululemon founder Chip Wilson …
2 hours ago The Series B round disclosed Wednesday was led by Ally Bridge Group and included Wilson's SOLVE FSHD, a venture philanthropy organization. The money will help …See details»
EPICS Therapeutics publishes the medicinal chemistry and efficacy …
Feb 10, 2025 EPICS Therapeutics announces the publication of its peer-reviewed article, “Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with …See details»
EPICS Therapeutics presents compelling in vivo efficacy in …
Gosselies, Belgium April 11th, 2023 – A proprietary, highly potent inhibitor of RNA methyltransferase 3 (METTL3) shows low nanomolar IC50 in proliferation assays with several …See details»